138 related articles for article (PubMed ID: 16534112)
1. Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers.
Li J; Zhuang Z; Okamoto H; Vortmeyer AO; Park DM; Furuta M; Lee YS; Oldfield EH; Zeng W; Weil RJ
Neurology; 2006 Mar; 66(5):733-6. PubMed ID: 16534112
[TBL] [Abstract][Full Text] [Related]
2. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme.
Vogel TW; Zhuang Z; Li J; Okamoto H; Furuta M; Lee YS; Zeng W; Oldfield EH; Vortmeyer AO; Weil RJ
Clin Cancer Res; 2005 May; 11(10):3624-32. PubMed ID: 15897557
[TBL] [Abstract][Full Text] [Related]
3. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.
Rorive S; Maris C; Debeir O; Sandras F; Vidaud M; Bièche I; Salmon I; Decaestecker C
J Neuropathol Exp Neurol; 2006 Aug; 65(8):794-807. PubMed ID: 16896313
[TBL] [Abstract][Full Text] [Related]
4. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables.
Zhou YH; Hess KR; Liu L; Linskey ME; Yung WK
Neuro Oncol; 2005 Oct; 7(4):485-94. PubMed ID: 16212813
[TBL] [Abstract][Full Text] [Related]
5. ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties.
Hubstenberger A; Labourdette G; Baudier J; Rousseau D
Exp Cell Res; 2008 Sep; 314(15):2870-83. PubMed ID: 18639545
[TBL] [Abstract][Full Text] [Related]
6. Search for a novel biomarker for the brain cancer astrocytoma by using surface enhanced laser desorption/ionisation (SELDI) technique.
Banerjee H; Hawkins Z; Williams J; Blackshear M; Sawyer C; Cezares L; Pramanik SK; Williams A
Cell Mol Biol (Noisy-le-grand); 2004 Sep; 50(6):733-6. PubMed ID: 15641164
[TBL] [Abstract][Full Text] [Related]
7. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas.
Maris C; Rorive S; Sandras F; D'Haene N; Sadeghi N; Bièche I; Vidaud M; Decaestecker C; Salmon I
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):316-29. PubMed ID: 17983425
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic histopathology, cytogenetics, and molecular markers of pediatric brain tumors.
Schofield DE
Neurosurg Clin N Am; 1992 Oct; 3(4):723-38. PubMed ID: 1327339
[TBL] [Abstract][Full Text] [Related]
9. Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma.
Sharma MK; Watson MA; Lyman M; Perry A; Aldape KD; Deák F; Gutmann DH
Neurology; 2006 Jan; 66(1):127-30. PubMed ID: 16401863
[TBL] [Abstract][Full Text] [Related]
10. Proteomic studies on low- and high-grade human brain astrocytomas.
Odreman F; Vindigni M; Gonzales ML; Niccolini B; Candiano G; Zanotti B; Skrap M; Pizzolitto S; Stanta G; Vindigni A
J Proteome Res; 2005; 4(3):698-708. PubMed ID: 15952716
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic imaging of high-grade astrocytoma: heterogeneity of clinical manifestation, image characteristics, and histopathological findings].
Okajima K; Ohta Y
Brain Nerve; 2012 Oct; 64(10):1151-7. PubMed ID: 23037605
[TBL] [Abstract][Full Text] [Related]
12. Outcome-based profiling of astrocytic tumours identifies prognostic gene expression signatures which link molecular and morphology-based pathology.
Beetz C; Bergner S; Brodoehl S; Brodhun M; Ewald C; Kalff R; Krüger J; Patt S; Kiehntopf M; Deufel T
Int J Oncol; 2006 Nov; 29(5):1183-91. PubMed ID: 17016650
[TBL] [Abstract][Full Text] [Related]
13. p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas.
Gaiser T; Becker MR; Meyer J; Habel A; Siegelin MD
Neurochem Int; 2009 Jun; 54(7):458-63. PubMed ID: 19428789
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
15. Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature.
Tchoghandjian A; Fernandez C; Colin C; El Ayachi I; Voutsinos-Porche B; Fina F; Scavarda D; Piercecchi-Marti MD; Intagliata D; Ouafik L; Fraslon-Vanhulle C; Figarella-Branger D
Brain; 2009 Jun; 132(Pt 6):1523-35. PubMed ID: 19336457
[TBL] [Abstract][Full Text] [Related]
16. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology.
Ikota H; Kinjo S; Yokoo H; Nakazato Y
Acta Neuropathol; 2006 May; 111(5):475-82. PubMed ID: 16598485
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
Hara A; Saegusa M; Ichinoe M; Okayasu I
J Clin Pathol; 2008 Mar; 61(3):287-92. PubMed ID: 18156430
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Tks5 expression in gliomas.
Stylli SS; I ST; Kaye AH; Lock P
J Clin Neurosci; 2012 Mar; 19(3):436-42. PubMed ID: 22249020
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules.
Liu X; Chen N; Wang X; He Y; Chen X; Huang Y; Yin W; Zhou Q
J Neuropathol Exp Neurol; 2006 Sep; 65(9):905-13. PubMed ID: 16957584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
